JP2012510477A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012510477A5 JP2012510477A5 JP2011538797A JP2011538797A JP2012510477A5 JP 2012510477 A5 JP2012510477 A5 JP 2012510477A5 JP 2011538797 A JP2011538797 A JP 2011538797A JP 2011538797 A JP2011538797 A JP 2011538797A JP 2012510477 A5 JP2012510477 A5 JP 2012510477A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- compound
- alkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 90
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 239000003446 ligand Substances 0.000 claims description 22
- 239000002184 metal Substances 0.000 claims description 19
- 229910052751 metal Inorganic materials 0.000 claims description 19
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 19
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims description 18
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims description 18
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000005647 linker group Chemical group 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 229910021645 metal ion Inorganic materials 0.000 claims description 6
- -1 activated dicarbonyl compound Chemical class 0.000 claims description 5
- 150000004696 coordination complex Chemical class 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229910052697 platinum Inorganic materials 0.000 claims description 4
- 125000006850 spacer group Chemical group 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 229910052793 cadmium Inorganic materials 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 229910052733 gallium Inorganic materials 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 229910052738 indium Inorganic materials 0.000 claims description 2
- 229910052741 iridium Inorganic materials 0.000 claims description 2
- 229910052748 manganese Inorganic materials 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229910052753 mercury Inorganic materials 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 229910052702 rhenium Inorganic materials 0.000 claims description 2
- 229910052707 ruthenium Inorganic materials 0.000 claims description 2
- 229910052721 tungsten Inorganic materials 0.000 claims description 2
- 229910052720 vanadium Inorganic materials 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical group CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 108010045325 cyclic arginine-glycine-aspartic acid peptide Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008906239 | 2008-12-02 | ||
| AU2008906239A AU2008906239A0 (en) | 2008-12-02 | Radiopharmaceuticals | |
| PCT/AU2009/001572 WO2010063069A1 (en) | 2008-12-02 | 2009-12-02 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015022109A Division JP5981580B2 (ja) | 2008-12-02 | 2015-02-06 | 放射性医用薬剤としての窒素含有大環状結合体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012510477A JP2012510477A (ja) | 2012-05-10 |
| JP2012510477A5 true JP2012510477A5 (cg-RX-API-DMAC7.html) | 2013-01-24 |
Family
ID=42232814
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011538797A Pending JP2012510477A (ja) | 2008-12-02 | 2009-12-02 | 放射性医用薬剤としての窒素含有大環状結合体 |
| JP2015022109A Active JP5981580B2 (ja) | 2008-12-02 | 2015-02-06 | 放射性医用薬剤としての窒素含有大環状結合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015022109A Active JP5981580B2 (ja) | 2008-12-02 | 2015-02-06 | 放射性医用薬剤としての窒素含有大環状結合体 |
Country Status (9)
| Country | Link |
|---|---|
| US (7) | US9701694B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2370447B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2012510477A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102300866B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009322081C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2745495C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3098225T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2712881T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010063069A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013003912A1 (en) * | 2011-07-07 | 2013-01-10 | Australian Nuclear Science And Technology Organisation | Cryptate compounds |
| PT2788353T (pt) * | 2011-12-06 | 2022-08-12 | Clarity Pharmaceuticals Pty Ltd | Ligandos amina com efeito de gaiola para metalo-radiofármacos |
| DK2788354T3 (en) | 2011-12-06 | 2017-03-06 | Univ Melbourne | FUNCTIONALIZATION OF CAGE AMINIGANDS FOR METALLO-RADIOPHARMACEUTICAL AGENTS |
| US9422286B2 (en) | 2014-01-27 | 2016-08-23 | Washington University | Metal-binding bifunctional compounds as diagnostic agents for Alzheimer's disease |
| GB201417067D0 (en) | 2014-09-26 | 2014-11-12 | South African Nuclear Energy | Radiopharmaceutical conjugate |
| BR112019009172A2 (pt) * | 2016-11-04 | 2019-07-16 | Clarity Pharmaceuticals Pty Ltd | formulações para radioterapia e diagnóstico por imagem. |
| CA3066525A1 (en) * | 2017-06-06 | 2018-12-13 | The University Of Melbourne | Radiopharmaceuticals, radioimaging agents, and uses thereof |
| WO2019195890A1 (en) * | 2018-04-11 | 2019-10-17 | Clarity Pharmaceuticals Pty Ltd | Formulations and kits for radiotherapy and diagnostic imaging |
| CN120365276A (zh) * | 2018-04-11 | 2025-07-25 | 透明医药有限公司 | 靶向化合物及其生产方法 |
| US20220313600A1 (en) * | 2019-05-24 | 2022-10-06 | Clarity Pharmaceuticals Limited | Formulations of psma imaging agents |
| CN115175910A (zh) * | 2019-11-08 | 2022-10-11 | 昆士兰大学 | 放射性标记的靶向配体 |
| WO2021150258A1 (en) * | 2020-01-26 | 2021-07-29 | Mainline Biosciences Llc | Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same |
| WO2021225760A1 (en) * | 2020-05-06 | 2021-11-11 | Cornell University | Copper-containing theragnostic compounds and methods of use |
| WO2022032353A1 (en) * | 2020-08-14 | 2022-02-17 | Clarity Pharmaceuticals Ltd | Radiopharmaceuticals, uses thereof, and methods for the production thereof |
| AU2023322240A1 (en) * | 2022-08-11 | 2025-02-20 | Clarity Pharmaceuticals Limited | Dimeric radiopharmaceuticals, compositions thereof and uses thereof |
| CN116589508A (zh) * | 2023-05-16 | 2023-08-15 | 洛阳师范学院 | 一种基于半夹心铑构筑单元的矩形分子大环化合物及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0001719A1 (en) | 1977-10-26 | 1979-05-02 | The Australian National University | Metal complexes, their preparation and production of hydrogen peroxide therewith |
| PT90959B (pt) * | 1988-06-24 | 1995-05-04 | Dow Chemical Co | Processo para a preparacao de quelantes macrociclicos bifuncionais, de seus complexos e seus conjugados com anticorpos |
| US5245055A (en) * | 1990-12-18 | 1993-09-14 | E. R. Squibb & Sons, Inc. | Process for preparing a cis oxabicyclo olefinic acid and ester from an oxabicyclo pyranol |
| JPH04244085A (ja) | 1990-12-21 | 1992-09-01 | Doujin Kagaku Kenkyusho:Kk | 蛍光性化合物、錯体、試薬および該試薬を用いる特異的結合アッセイ |
| CN1152880A (zh) * | 1994-04-22 | 1997-06-25 | 孟山都公司 | 使用含氮大环配拉体的金属络合物的诊断图像分析的方法 |
| WO1995031202A1 (en) * | 1994-05-17 | 1995-11-23 | Commonwealth Scientific And Industrial Research Organisation | Cage compounds, processes for their preparation and their use as antiviral agents |
| AUPP803899A0 (en) * | 1999-01-05 | 1999-01-28 | Australian National University, The | Cryptate compounds and methods for diagnosis and therapy. |
| US6107326A (en) | 1999-04-12 | 2000-08-22 | Cytopharm, Inc. | Porphycenes for treatment of microbial populations |
| GB0116815D0 (en) | 2001-07-10 | 2001-08-29 | Nycomed Amersham Plc | Improved chelator conjugates |
| EP1331012A1 (en) * | 2002-01-29 | 2003-07-30 | BRACCO IMAGING S.p.A. | Responsive paramagnetic MRI contrast agents |
| FI20031528A0 (fi) * | 2003-10-17 | 2003-10-17 | Ctt Cancer Targeting Tech Oy | Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi |
| US9056129B2 (en) * | 2007-02-09 | 2015-06-16 | Northeastern University | Precision-guided nanoparticle systems for drug delivery |
-
2009
- 2009-12-02 DK DK16172324.2T patent/DK3098225T3/en active
- 2009-12-02 US US13/132,194 patent/US9701694B2/en active Active
- 2009-12-02 JP JP2011538797A patent/JP2012510477A/ja active Pending
- 2009-12-02 WO PCT/AU2009/001572 patent/WO2010063069A1/en not_active Ceased
- 2009-12-02 EP EP09829884.7A patent/EP2370447B1/en active Active
- 2009-12-02 ES ES16172324T patent/ES2712881T3/es active Active
- 2009-12-02 EP EP16172324.2A patent/EP3098225B1/en active Active
- 2009-12-02 AU AU2009322081A patent/AU2009322081C1/en active Active
- 2009-12-02 CA CA2745495A patent/CA2745495C/en active Active
- 2009-12-02 CN CN200980156413.6A patent/CN102300866B/zh active Active
-
2015
- 2015-02-06 JP JP2015022109A patent/JP5981580B2/ja active Active
-
2017
- 2017-06-02 US US15/612,185 patent/US10301326B2/en active Active
- 2017-06-02 US US15/612,009 patent/US10544164B2/en active Active
-
2019
- 2019-04-09 US US16/378,716 patent/US10870664B2/en active Active
- 2019-12-12 US US16/712,485 patent/US11111254B2/en active Active
-
2021
- 2021-08-04 US US17/393,837 patent/US11905301B2/en active Active
-
2023
- 2023-10-31 US US18/498,744 patent/US20240190897A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012510477A5 (cg-RX-API-DMAC7.html) | ||
| JP4560210B2 (ja) | 薬物複合体 | |
| JP5981580B2 (ja) | 放射性医用薬剤としての窒素含有大環状結合体 | |
| JP2020508985A5 (cg-RX-API-DMAC7.html) | ||
| JP2008533191A5 (cg-RX-API-DMAC7.html) | ||
| JP2014503574A5 (cg-RX-API-DMAC7.html) | ||
| US20200069698A1 (en) | Texaphyrin-pt(iv) conjugates and compositions for use in overcoming platinum resistance | |
| JP2020531591A (ja) | 相乗的抗癌活性を有する中間体薬剤およびポリエチレングリコール共役相乗的抗癌薬、ならびにその製造方法およびその使用 | |
| AU2019383466B2 (en) | Therapeutic dendrimer | |
| CA3120881A1 (en) | Dendrimer for therapy and imaging | |
| JP2010511687A5 (cg-RX-API-DMAC7.html) | ||
| US20160220689A1 (en) | Macromolecules of dendrimer-platinum conjugates | |
| CN104169291B (zh) | 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法 | |
| DK2788354T3 (en) | FUNCTIONALIZATION OF CAGE AMINIGANDS FOR METALLO-RADIOPHARMACEUTICAL AGENTS | |
| Uhlir et al. | Specific sequestering agents for the actinides. 21. Synthesis and initial biological testing of octadentate mixed catecholate-hydroxypyridinonate ligands | |
| JP2000509030A (ja) | グリコペプチド化合物 | |
| CN120731208A (zh) | 新型喜树碱衍生物及其偶联物 | |
| JP2015500246A5 (cg-RX-API-DMAC7.html) | ||
| AU2012278938A1 (en) | Cryptate compounds | |
| JP2005524622A5 (cg-RX-API-DMAC7.html) | ||
| JP2006520768A (ja) | 金属イオンのキレート化剤として有用な窒素含有多環式誘導体およびそれらの用途 | |
| US20220395525A1 (en) | Therapeutic dendrimer | |
| US20250066411A1 (en) | Glycomimetic binders for l-sign | |
| CN116234584A (zh) | 天冬阿糖胞苷的结晶形式 | |
| JP7671768B2 (ja) | 抗体の部位特異的修飾のための方法 |